Sangamo exec sells 69,827 shares in market trade
Sangamo Therapeutics executive Gregory D. Davis, Head of Research & Technology, sold common stock in an open-market transaction.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Sangamo Therapeutics executive Gregory D. Davis, Head of Research & Technology, sold common stock in an open-market transaction. On April 22, 2026, he sold 69,827 shares of Sangamo Therapeutics common stock at a weighted-average price of $0.2534 per share, with individual trades ranging from $0.2533 to $0.2568. After this sale, Davis directly holds 115,284 shares of the company’s common stock.
Insider Trade Summary
Net Seller: 69,827 shares
Net Sell
1 txn
Insider
Davis Gregory D
Role
Head of Research & Technology
Sold
69,827 shs ($18K)
Share of Position Sold
37.7%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 69,827 | $0.2534 | $18K |
Holdings After Transaction:
Common Stock — 115,284 shares (Direct)
Holdings Before and After:
Common Stock, 185,111 to 115,284 shares (Direct)
Other Insiders: 1 other insider reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (1)
- F1. The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $0.2533 to $0.2568, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Key Figures
Shares sold: 69,827 shares
Weighted-average sale price: $0.2534 per share
Post-sale holdings: 115,284 shares
+2 more
5 metrics
Shares sold
69,827 shares
Open-market sale of common stock on April 22, 2026
Weighted-average sale price
$0.2534 per share
Average price for multiple trades in the reported sale
Post-sale holdings
115,284 shares
Common stock directly owned after the transaction
Price range of trades
$0.2533–$0.2568 per share
Range of individual sale prices within the transaction
Net shares sold
69,827 shares
Net change in position from this Form 4, all sales
Key Terms
open-market sale, weighted-average price, Common Stock, Form 4
4 terms
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted-average price financial
"The price reported is a weighted-average price."
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
Common Stock financial
"security_title": "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Sangamo Therapeutics (SGMO) report for Gregory D. Davis?
Sangamo Therapeutics reported that executive Gregory D. Davis completed an open-market sale of 69,827 shares of common stock. The transaction occurred on April 22, 2026 and was executed at a weighted-average price of $0.2534 per share.
What type of transaction is disclosed for SGMO executive Gregory D. Davis?
The filing describes the transaction as an open-market sale of Sangamo Therapeutics common stock by executive Gregory D. Davis. It is coded as a “S” transaction, meaning a sale in the open market or a private transaction under SEC reporting rules.
Does the Sangamo Therapeutics (SGMO) Form 4 mention a weighted-average price for the Davis sale?
Yes. The Form 4 explains that the reported price is a weighted-average of multiple trades. Shares were sold at prices between $0.2533 and $0.2568, with the weighted-average sale price disclosed as $0.2534 per share in the filing.
Who is the insider involved in the latest SGMO Form 4 and what is his role?
The insider is Gregory D. Davis, who serves as Head of Research & Technology at Sangamo Therapeutics. The Form 4 attributes the open-market sale of common stock directly to him, reflecting his executive role and direct ownership position in the company.
AI-generated analysis. How Rhea-AI works. Not financial advice.
